Q3 2020 13F Holders as of 9/30/2020
-
Type / Class
-
Equity / Common Stock, $0.0001 par value per share
-
Shares outstanding
-
30.3M
-
Number of holders
-
49
-
Total 13F shares, excl. options
-
11.8M
-
Shares change
-
+855K
-
Total reported value, excl. options
-
$455M
-
Value change
-
+$33.8M
-
Number of buys
-
23
-
Number of sells
-
-23
-
Price
-
$38.57
Significant Holders of Keros Therapeutics, Inc. - Common Stock, $0.0001 par value per share (KROS) as of Q3 2020
57 filings reported holding KROS - Keros Therapeutics, Inc. - Common Stock, $0.0001 par value per share as of Q3 2020.
Keros Therapeutics, Inc. - Common Stock, $0.0001 par value per share (KROS) has 49 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 11.8M shares
of 30.3M outstanding shares and own 38.9% of the company stock.
Largest 10 shareholders include RA CAPITAL MANAGEMENT, L.P. (1.88M shares), FMR LLC (1.79M shares), ORBIMED ADVISORS LLC (1.68M shares), Logos Global Management LP (1.6M shares), Foresite Capital Management IV, LLC (1.41M shares), VR Adviser, LLC (672K shares), BlackRock Inc. (655K shares), CHI Advisors LLC (569K shares), VANGUARD GROUP INC (299K shares), and Nantahala Capital Management, LLC (277K shares).
This table shows the top 49 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.